**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

Claims 1-142 (Canceled).

Claim 143. (Previously Presented) A method for impairing cellular peptide processing for MHC presentation comprising

treating cells with a substance

wherein the substance is characterized in that tumor cells treated with the substance are subject to specific lysis by CTL elicited by endogenous MHC class I dependent antigens of the TAP-deficient variant of said tumor cell which has been transfected with the stimulatory molecule B7-1;

and thereby inducing immunological effector cells specific for endogenous epitopes associated with impaired cellular peptide processing for MHC presentation.

Claim 144. (Previously Presented) The method of claim 143, wherein the substance is selected from the group consisting of substances that inhibit the function of TAP and substances that inhibit the expression of TAP.

Claim 145. (Previously Presented) The method of claim 143, wherein the substance is selected from the group consisting of ICP47 of HSV type 1, IE 12 of HSV type 2, a gene encoding a TAP inhibitor, a nucleotide sequence that is complementary to mRNA or DNA sequences encoding TAP, antisense oligonucleotides, and RNA destroying ribozyme.

Claim 146. (Previously Presented) The method of claim 143, wherein the substance inhibits the function and/or expression of the proteasome.

Claim 147. (Previously Presented) The method of claim 143, wherein the substance is selected from the group consisting of a peptide aldehyde Z-Leu-Leu-H, Lactacystin, DNA

encoding a proteasome inhibitor, a nucleotide sequence that is complementary at least in part to the mRNA or DNA sequences encoding proteasome, antisense oligonucleotides and RNA-destroying ribozyme.

Claim 148. (Currently Amended) A process comprising

treating cells in vitro with an effective dose of a substance that impairs cellular peptide processing for MHC presentation,

wherein the substance is characterized in that tumor cells treated with the substance are subject to specific lysis by CTL elicited by endogenous MHC class I dependent antigens of the TAP-deficient variant of said tumor cell which has been transfected with the stimulatory molecule B7-1; and

~~identifying~~ isolating cells which activate CD8+ T lymphocytes that selectively recognize cells showing endogenous epitopes associated with impaired cellular peptide processing for MHC presentation.

Claim 149. (Previously Presented) A process according to claim 148, wherein the substance inhibits the function and/or expression of TAP.

Claim 150. (Previously Presented) A process according to claim 149, wherein the substance is selected from the group consisting of ICP47 of HSV type 1, IE 12 of HSV type 2, a nucleotide sequence encoding a TAP inhibitor, a nucleotide sequence encoding that is complementary at least in part to the mRNA or DNA sequences encoding TAP, antisense oligonucleotides, and RNA-destroying ribozyme.

Claim 151. (Previously Presented) A process according to claim 148, wherein the substance inhibits the function and/or expression of the proteasome.

Claim 152. (Previously Presented) A process according to claim 151, wherein the substance is selected from the group consisting of a peptide aldehyde Z-Leu-Leu-H, Lactacystin, a nucleotide sequence encoding a proteasome inhibitor, a nucleotide sequence that is complementary to an mRNA or DNA sequence encoding proteasome, antisense oligonucleotides and RNA-destroying ribozyme.

Claim 153. (Previously Presented) A process according to claim 148, wherein the cells are autologous and/or hematopoetic cells.

Claim 154. (Previously Presented) A process according to claim 153, wherein the autologous and/or hematopoetic cells are dendritic cells or cells from cancer tissues.

Claim 155. (Currently Amended) A process comprising

a) stimulating isolated immunological effector cells in vitro with cells ~~identified~~ isolated according to the method of ~~claims~~ claim148; and

b) ~~identifying~~ isolating immunological effector cells that selectively recognize cells showing impaired cellular peptide processing for MHC presentation.

Claim 156. (Previously Presented) The process of claim 155, wherein the immunological effector cells are CD8+ T lymphocytes.

Claim 157. (Currently Amended) A composition comprising cells ~~identified~~ isolated according to the method of claim 148.

Claim 158. (Previously Presented) A process comprising

administering to a mammal immunological effector cells that selectively recognize cells showing impaired cellular peptide processing for MHC presentation.

Claim 159. (Previously Presented) A composition comprising

a substance that impairs cellular peptide processing for MHC presentation,

and thereby induces immunological effector cells specific for endogenous epitopes associated with impaired cellular peptide processing for MHC presentation,

the substance being characterized in that tumor cells treated with the substance are subject to specific lysis by CTL elicited by endogenous MHC class I dependent antigens of the TAP-deficient variant of said tumor cell which has been transfected with the stimulatory molecule B7-1; and

a pharmaceutically acceptable adjuvant selected from cytokines, genes for cytokines, costimulatory molecules, gold beads and/or liposomes.

Claim 160. (Currently Amended) A composition comprising

cells ~~identified~~ isolated according to the method of claim 148, or antigens or epitopes expressed by such cells; and

a pharmaceutically acceptable additive.

Claim 161. (Currently Amended) A composition comprising immunological effector cells ~~identified~~ isolated according to the method of claim 155.

Claim 162. (Previously Presented) A kit comprising

a substance that impairs cellular peptide processing for MHC presentation, and thereby inducing immunological effector cells specific for endogenous epitopes associated with impaired cellular peptide processing for MHC presentation,

the substance being characterized in that tumor cells treated with the substance are subject to specific lysis by CTL elicited by endogenous MHC class I dependent antigens of the TAP-deficient variant of said tumor cell which has been transfected with the stimulatory molecule B7-1; and

cytokines, DNA encoding cytokines, costimulatory molecules, gold beads and/or liposomes.

Claim 163. (New) The method according to claim 148, further comprising

stimulating isolated immunological effector cells in vitro with said isolated cells which activate CD8+ T lymphocytes that selectively recognize cells showing endogenous epitopes associated with impaired cellular peptide processing for MHC presentation; and

isolating immunological effector cells that selectively recognize cells showing impaired cellular peptide processing for MHC presentation.

Claims 164 (New) A composition comprising isolated immunological effector cells that selectively recognizes cells showing impaired cellular peptide processing for MHC presentation isolated according to the method of claim 163.